Eczema drug delivery showdown: autoinjector vs vial
NCT ID NCT06438263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested how well the body absorbs rocatinlimab, a drug for atopic dermatitis (eczema), when given through an autoinjector pen compared to a traditional vial and syringe. It involved 231 healthy adults aged 18-60. The goal was to see if the autoinjector delivers the drug similarly to the vial, which could make future treatments easier for patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4968, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
-
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, 53704-2526, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common antibiotic boost eczema treatment?
- New biologic drug aims to clear stubborn eczema in just 24 weeks
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could a simple body wash and cream soothe eczema without a prescription?
- Skin sodium levels may hold clues to eczema in older adults
- Could a daily powder boost skin elasticity and fight fatigue?